Hepcidin: clinical utility as a diagnostic tool and therapeutic target (Q37890241)

24 August 2017

1 reference

title

Hepcidin: clinical utility as a diagnostic tool and therapeutic target (English)

1 reference

24 August 2017

0 references

Daniel W Coyne

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

15 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

80

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

240-244

1 reference

Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Regulation of iron metabolism by hepcidin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

The serine protease TMPRSS6 is required to sense iron deficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Hepcidin, a new iron regulatory peptide

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

The role of hepcidin in iron metabolism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Suppression of hepcidin during anemia requires erythropoietic activity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Hepcidin assays: ironing out some details.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Hepcidin--a potential novel biomarker for iron status in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Variability of ferritin measurements in chronic kidney disease; implications for iron management.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Severe iron deficiency anemia in transgenic mice expressing liver hepcidin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Iron-refractory iron deficiency anemia: new molecular mechanisms.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

A tincture of hepcidin cures all: the potential for hepcidin therapeutics.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.141

7 January 2021

Identifiers

DOI

10.1038/KI.2011.141

1 reference

Dimensions Publication ID

24 August 2017

1041099837

0 references

1 reference